Goldman Sachs
EPIX

Goldman Sachs’s ESSA Pharma EPIX Stock Holding History

Goldman Sachs’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,531
Closed -$45K – 6050
2022
Q3 		$45K Buy
24,531
+12,792
+109% +$33.7K ﹤0.01% 5813
2022
Q2 		$37K Sell
11,739
-65,427
-85% -$366K ﹤0.01% 6086
2022
Q1 		$477K Sell
77,166
-17,224
-18% -$151K ﹤0.01% 5346
2021
Q4 		$1.34M Sell
94,390
-27,211
-22% -$303K ﹤0.01% 4598
2021
Q3 		$973K Buy
121,601
+54,827
+82% +$872K ﹤0.01% 4768
2021
Q2 		$1.91M Buy
66,774
+25,783
+63% +$749K ﹤0.01% 4245
2021
Q1 		$1.19M Buy
40,991
+30,707
+299% +$714K ﹤0.01% 4462
2020
Q4 		$123K Buy
+10,284
New +$72.4K ﹤0.01% 5254

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Goldman Sachs's EPIX Position: Q4 2022 in Review

Goldman Sachs sold out of ESSA Pharma (EPIX) in Q4 2022, closing a stake of 24,531 shares — an estimated $45K sold.

Goldman Sachs first reported a position in EPIX in Q4 2020 and held it in 8 quarters. The position peaked at $1.91M in Q2 2021. 45 funds tracked by Wall St. Rank hold EPIX as of Q4 2022.

  • Goldman Sachs reported no remaining ESSA Pharma position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 24,531 ESSA Pharma shares in Q4 2022, an estimated $45K.
  • Goldman Sachs first reported a position in ESSA Pharma in Q4 2020 and held it in 8 quarters.
  • Goldman Sachs's ESSA Pharma position peaked at $1.91M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.